Trial Profile
A Phase 1/2 Study of Vadastuximab Talirine (SGN-CD33A) in Combination With Azacitidine in Patients With Previously Untreated International Prognostic Scoring System (IPSS) Intermediate-2 or High Risk Myelodysplastic Syndrome (MDS)
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 28 Oct 2020
Price :
$35
*
At a glance
- Drugs Vadastuximab talirine (Primary) ; Azacitidine; Azacitidine
- Indications Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- Sponsors Seagen
- 03 Jan 2018 Status changed from suspended to discontinued.
- 19 Jun 2017 According to a company media release, Seattle Genetics is suspending patient enrollment and treatment in all of its vadastuximab talirine clinical trials based on unfavourable results obtained in the phase III CASCADE trial.
- 19 Jun 2017 Status changed from recruiting to suspended according to a Seattle Genetics media release.